Review



easysep negative selection human progenitor cell enrichment cocktail (stemcell technologies)  (STEMCELL Technologies Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    STEMCELL Technologies Inc easysep negative selection human progenitor cell enrichment cocktail (stemcell technologies)
    Targeting Polθ + PARP and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells. A, Western blot analysis showing the expression of indicated proteins in the nuclear fractions of Nalm6(RAD54+/+) and Nalm6(RAD54−/−) isogenic cell lines. B, HR activity in Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells: results represent mean % SD of GFP+ cells in RFP+ cells. Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells were treated for 72 hours (C) and 12 hours (D) with 25 mmol/L Polθi ART558, 2.5 nmol/L PARPi talazoparib, 10 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean number SD of colony numbers (C) and mean % of tail DNA SD (D). E, Western blot analysis showing the expression of indicated proteins in the nuclear and cytosolic fractions of HEL cells with tet-inducible IDH1wt or IDH1(R132H) mutant. F, HR activity in HEL cells expressing IDH1wt or IDH1(R132H) mutant: results represent mean % SD of GFP+ cells in RFP+ cells. HEL cells expressing IDH1wt or IDH1(R132H) mutant were treated for 72 hours (G) and 12 hours (H) with 25 mmol/L Polθi ART558, 1 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean % SD of colony numbers when compared with untreated cells (G) and mean % of tail DNA SD (H). I, HR activity in <t>Lin-CD34+</t> cells from HR-proficient and HR-deficient AMLs (n = 3 of each). Results represent mean % SD of GFP+ cells in RFP+ cells. J, <t>Lin-CD34+</t> cells from HR-proficient and HR-deficient AMLs (n = 3 of each) were treated with 25 mmol/L Polθi ART558, 1.25 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL–dopa and the indicated combinations. Results represent mean % SD of colonies in comparison with untreated cells. K, Survival curves of the AML mice treated with vehicle (C), Polθi RP6685, PARPi olaparib, and the combination. (B–D and F–J) Statistical significance when compared with: # another group, + control, and * corresponding individual treatments. K, ***, P < 0.001 in comparison to other groups.
    Easysep Negative Selection Human Progenitor Cell Enrichment Cocktail (Stemcell Technologies), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/easysep negative selection human progenitor cell enrichment cocktail (stemcell technologies)/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    easysep negative selection human progenitor cell enrichment cocktail (stemcell technologies) - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination–Deficient Leukemia Cells"

    Article Title: Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination–Deficient Leukemia Cells

    Journal: Molecular cancer research : MCR

    doi: 10.1158/1541-7786.MCR-22-1035

    Targeting Polθ + PARP and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells. A, Western blot analysis showing the expression of indicated proteins in the nuclear fractions of Nalm6(RAD54+/+) and Nalm6(RAD54−/−) isogenic cell lines. B, HR activity in Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells: results represent mean % SD of GFP+ cells in RFP+ cells. Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells were treated for 72 hours (C) and 12 hours (D) with 25 mmol/L Polθi ART558, 2.5 nmol/L PARPi talazoparib, 10 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean number SD of colony numbers (C) and mean % of tail DNA SD (D). E, Western blot analysis showing the expression of indicated proteins in the nuclear and cytosolic fractions of HEL cells with tet-inducible IDH1wt or IDH1(R132H) mutant. F, HR activity in HEL cells expressing IDH1wt or IDH1(R132H) mutant: results represent mean % SD of GFP+ cells in RFP+ cells. HEL cells expressing IDH1wt or IDH1(R132H) mutant were treated for 72 hours (G) and 12 hours (H) with 25 mmol/L Polθi ART558, 1 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean % SD of colony numbers when compared with untreated cells (G) and mean % of tail DNA SD (H). I, HR activity in Lin-CD34+ cells from HR-proficient and HR-deficient AMLs (n = 3 of each). Results represent mean % SD of GFP+ cells in RFP+ cells. J, Lin-CD34+ cells from HR-proficient and HR-deficient AMLs (n = 3 of each) were treated with 25 mmol/L Polθi ART558, 1.25 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL–dopa and the indicated combinations. Results represent mean % SD of colonies in comparison with untreated cells. K, Survival curves of the AML mice treated with vehicle (C), Polθi RP6685, PARPi olaparib, and the combination. (B–D and F–J) Statistical significance when compared with: # another group, + control, and * corresponding individual treatments. K, ***, P < 0.001 in comparison to other groups.
    Figure Legend Snippet: Targeting Polθ + PARP and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells. A, Western blot analysis showing the expression of indicated proteins in the nuclear fractions of Nalm6(RAD54+/+) and Nalm6(RAD54−/−) isogenic cell lines. B, HR activity in Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells: results represent mean % SD of GFP+ cells in RFP+ cells. Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells were treated for 72 hours (C) and 12 hours (D) with 25 mmol/L Polθi ART558, 2.5 nmol/L PARPi talazoparib, 10 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean number SD of colony numbers (C) and mean % of tail DNA SD (D). E, Western blot analysis showing the expression of indicated proteins in the nuclear and cytosolic fractions of HEL cells with tet-inducible IDH1wt or IDH1(R132H) mutant. F, HR activity in HEL cells expressing IDH1wt or IDH1(R132H) mutant: results represent mean % SD of GFP+ cells in RFP+ cells. HEL cells expressing IDH1wt or IDH1(R132H) mutant were treated for 72 hours (G) and 12 hours (H) with 25 mmol/L Polθi ART558, 1 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean % SD of colony numbers when compared with untreated cells (G) and mean % of tail DNA SD (H). I, HR activity in Lin-CD34+ cells from HR-proficient and HR-deficient AMLs (n = 3 of each). Results represent mean % SD of GFP+ cells in RFP+ cells. J, Lin-CD34+ cells from HR-proficient and HR-deficient AMLs (n = 3 of each) were treated with 25 mmol/L Polθi ART558, 1.25 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL–dopa and the indicated combinations. Results represent mean % SD of colonies in comparison with untreated cells. K, Survival curves of the AML mice treated with vehicle (C), Polθi RP6685, PARPi olaparib, and the combination. (B–D and F–J) Statistical significance when compared with: # another group, + control, and * corresponding individual treatments. K, ***, P < 0.001 in comparison to other groups.

    Techniques Used: Western Blot, Expressing, Activity Assay, Mutagenesis, Comparison, Control



    Similar Products

    easysep negative selection human progenitor cell enrichment cocktail (stemcell technologies)  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep negative selection human progenitor cell enrichment cocktail (stemcell technologies)
    Targeting Polθ + PARP and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells. A, Western blot analysis showing the expression of indicated proteins in the nuclear fractions of Nalm6(RAD54+/+) and Nalm6(RAD54−/−) isogenic cell lines. B, HR activity in Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells: results represent mean % SD of GFP+ cells in RFP+ cells. Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells were treated for 72 hours (C) and 12 hours (D) with 25 mmol/L Polθi ART558, 2.5 nmol/L PARPi talazoparib, 10 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean number SD of colony numbers (C) and mean % of tail DNA SD (D). E, Western blot analysis showing the expression of indicated proteins in the nuclear and cytosolic fractions of HEL cells with tet-inducible IDH1wt or IDH1(R132H) mutant. F, HR activity in HEL cells expressing IDH1wt or IDH1(R132H) mutant: results represent mean % SD of GFP+ cells in RFP+ cells. HEL cells expressing IDH1wt or IDH1(R132H) mutant were treated for 72 hours (G) and 12 hours (H) with 25 mmol/L Polθi ART558, 1 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean % SD of colony numbers when compared with untreated cells (G) and mean % of tail DNA SD (H). I, HR activity in <t>Lin-CD34+</t> cells from HR-proficient and HR-deficient AMLs (n = 3 of each). Results represent mean % SD of GFP+ cells in RFP+ cells. J, <t>Lin-CD34+</t> cells from HR-proficient and HR-deficient AMLs (n = 3 of each) were treated with 25 mmol/L Polθi ART558, 1.25 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL–dopa and the indicated combinations. Results represent mean % SD of colonies in comparison with untreated cells. K, Survival curves of the AML mice treated with vehicle (C), Polθi RP6685, PARPi olaparib, and the combination. (B–D and F–J) Statistical significance when compared with: # another group, + control, and * corresponding individual treatments. K, ***, P < 0.001 in comparison to other groups.
    Easysep Negative Selection Human Progenitor Cell Enrichment Cocktail (Stemcell Technologies), supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/easysep negative selection human progenitor cell enrichment cocktail (stemcell technologies)/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    easysep negative selection human progenitor cell enrichment cocktail (stemcell technologies) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    easysep negative selection human progenitor cell enrichment cocktail  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc easysep negative selection human progenitor cell enrichment cocktail
    Targeting Polθ + PARP and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells. A, Western blot analysis showing the expression of indicated proteins in the nuclear fractions of Nalm6(RAD54+/+) and Nalm6(RAD54−/−) isogenic cell lines. B, HR activity in Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells: results represent mean % SD of GFP+ cells in RFP+ cells. Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells were treated for 72 hours (C) and 12 hours (D) with 25 mmol/L Polθi ART558, 2.5 nmol/L PARPi talazoparib, 10 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean number SD of colony numbers (C) and mean % of tail DNA SD (D). E, Western blot analysis showing the expression of indicated proteins in the nuclear and cytosolic fractions of HEL cells with tet-inducible IDH1wt or IDH1(R132H) mutant. F, HR activity in HEL cells expressing IDH1wt or IDH1(R132H) mutant: results represent mean % SD of GFP+ cells in RFP+ cells. HEL cells expressing IDH1wt or IDH1(R132H) mutant were treated for 72 hours (G) and 12 hours (H) with 25 mmol/L Polθi ART558, 1 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean % SD of colony numbers when compared with untreated cells (G) and mean % of tail DNA SD (H). I, HR activity in <t>Lin-CD34+</t> cells from HR-proficient and HR-deficient AMLs (n = 3 of each). Results represent mean % SD of GFP+ cells in RFP+ cells. J, <t>Lin-CD34+</t> cells from HR-proficient and HR-deficient AMLs (n = 3 of each) were treated with 25 mmol/L Polθi ART558, 1.25 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL–dopa and the indicated combinations. Results represent mean % SD of colonies in comparison with untreated cells. K, Survival curves of the AML mice treated with vehicle (C), Polθi RP6685, PARPi olaparib, and the combination. (B–D and F–J) Statistical significance when compared with: # another group, + control, and * corresponding individual treatments. K, ***, P < 0.001 in comparison to other groups.
    Easysep Negative Selection Human Progenitor Cell Enrichment Cocktail, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/easysep negative selection human progenitor cell enrichment cocktail/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    easysep negative selection human progenitor cell enrichment cocktail - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Targeting Polθ + PARP and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells. A, Western blot analysis showing the expression of indicated proteins in the nuclear fractions of Nalm6(RAD54+/+) and Nalm6(RAD54−/−) isogenic cell lines. B, HR activity in Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells: results represent mean % SD of GFP+ cells in RFP+ cells. Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells were treated for 72 hours (C) and 12 hours (D) with 25 mmol/L Polθi ART558, 2.5 nmol/L PARPi talazoparib, 10 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean number SD of colony numbers (C) and mean % of tail DNA SD (D). E, Western blot analysis showing the expression of indicated proteins in the nuclear and cytosolic fractions of HEL cells with tet-inducible IDH1wt or IDH1(R132H) mutant. F, HR activity in HEL cells expressing IDH1wt or IDH1(R132H) mutant: results represent mean % SD of GFP+ cells in RFP+ cells. HEL cells expressing IDH1wt or IDH1(R132H) mutant were treated for 72 hours (G) and 12 hours (H) with 25 mmol/L Polθi ART558, 1 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean % SD of colony numbers when compared with untreated cells (G) and mean % of tail DNA SD (H). I, HR activity in Lin-CD34+ cells from HR-proficient and HR-deficient AMLs (n = 3 of each). Results represent mean % SD of GFP+ cells in RFP+ cells. J, Lin-CD34+ cells from HR-proficient and HR-deficient AMLs (n = 3 of each) were treated with 25 mmol/L Polθi ART558, 1.25 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL–dopa and the indicated combinations. Results represent mean % SD of colonies in comparison with untreated cells. K, Survival curves of the AML mice treated with vehicle (C), Polθi RP6685, PARPi olaparib, and the combination. (B–D and F–J) Statistical significance when compared with: # another group, + control, and * corresponding individual treatments. K, ***, P < 0.001 in comparison to other groups.

    Journal: Molecular cancer research : MCR

    Article Title: Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination–Deficient Leukemia Cells

    doi: 10.1158/1541-7786.MCR-22-1035

    Figure Lengend Snippet: Targeting Polθ + PARP and Polθ + RAD52 induced dual synthetic lethality against HR-deficient leukemia cells. A, Western blot analysis showing the expression of indicated proteins in the nuclear fractions of Nalm6(RAD54+/+) and Nalm6(RAD54−/−) isogenic cell lines. B, HR activity in Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells: results represent mean % SD of GFP+ cells in RFP+ cells. Nalm6(RAD54+/+) and Nalm6(RAD54−/−) cells were treated for 72 hours (C) and 12 hours (D) with 25 mmol/L Polθi ART558, 2.5 nmol/L PARPi talazoparib, 10 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean number SD of colony numbers (C) and mean % of tail DNA SD (D). E, Western blot analysis showing the expression of indicated proteins in the nuclear and cytosolic fractions of HEL cells with tet-inducible IDH1wt or IDH1(R132H) mutant. F, HR activity in HEL cells expressing IDH1wt or IDH1(R132H) mutant: results represent mean % SD of GFP+ cells in RFP+ cells. HEL cells expressing IDH1wt or IDH1(R132H) mutant were treated for 72 hours (G) and 12 hours (H) with 25 mmol/L Polθi ART558, 1 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL-dopa and the indicated combinations. Results show mean % SD of colony numbers when compared with untreated cells (G) and mean % of tail DNA SD (H). I, HR activity in Lin-CD34+ cells from HR-proficient and HR-deficient AMLs (n = 3 of each). Results represent mean % SD of GFP+ cells in RFP+ cells. J, Lin-CD34+ cells from HR-proficient and HR-deficient AMLs (n = 3 of each) were treated with 25 mmol/L Polθi ART558, 1.25 mmol/L PARPi olaparib, 2.5 mmol/L RAD52i 6-hydroxy-DL–dopa and the indicated combinations. Results represent mean % SD of colonies in comparison with untreated cells. K, Survival curves of the AML mice treated with vehicle (C), Polθi RP6685, PARPi olaparib, and the combination. (B–D and F–J) Statistical significance when compared with: # another group, + control, and * corresponding individual treatments. K, ***, P < 0.001 in comparison to other groups.

    Article Snippet: Lin − CD34 + cells were obtained from mononuclear fractions by magnetic sorting using the EasySep negative selection human progenitor cell enrichment cocktail followed by human CD34 positive selection cocktail (Stemcell Technologies) as described before ( 3 ).

    Techniques: Western Blot, Expressing, Activity Assay, Mutagenesis, Comparison, Control